Final exam l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 44

Final Exam PowerPoint PPT Presentation


  • 111 Views
  • Uploaded on
  • Presentation posted in: General

Final Exam. Tuesday, 6/5, 2 PM Closed book Essay and MC/TF Determining Energy Needs p234-246 Indirect calorimetry Be able to do the calculations given RQ table, VO2, VCO2 Principles of indirect calorimetry Don’t memorize H-B or WHO equations. Final Exam. Protein status

Download Presentation

Final Exam

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Final exam l.jpg

Final Exam

  • Tuesday, 6/5, 2 PM

  • Closed book

    • Essay and MC/TF

  • Determining Energy Needs

    • p234-246

    • Indirect calorimetry

    • Be able to do the calculations given RQ table, VO2, VCO2

    • Principles of indirect calorimetry

    • Don’t memorize H-B or WHO equations


Final exam2 l.jpg

Final Exam

  • Protein status

    • AMA (will give you equations, 233-234)

    • Biochemical assessments (321-327)

  • Iron status (327-332)

    • Know markers (and their rationale) of iron status

    • Be able to interpret lab values

  • Glucose (fasting & GTT) (303-307)

    • principle & interpretation

  • Lipoproteins & CHD (262-272)

    • Assessment only, not treatment

    • CHD risk assessment using ATP III

    • Know cut points


Update detection evaluation and treatment of high blood cholesterol in adults atp iii l.jpg

Update: Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III)

David L. Gee, PhD

Professor of Food Science and Nutrition

Central Washington University


National cholesterol education program ncep history l.jpg

National Cholesterol Education Program (NCEP)History

  • Adult Treatment Panel I (ATP I)

    • 1988

    • strategy for primary prevention of CHD

    • established cutoff values for TC, HDL-C, LDL-C and CHD risk factors


National cholesterol education program ncep l.jpg

National Cholesterol Education Program (NCEP)

  • Children’s Treatment Panel

    • 1991

  • ATP II

    • 1993

    • reaffirmed ATP I

    • secondary prevention of CHD


National cholesterol education program ncep6 l.jpg

National Cholesterol Education Program (NCEP)

  • ATP III

    • May 2001

    • reaffirms ATP I, II

  • New features

    • primary prevention in persons with multiple risk factors

    • modifies lipid classifications

    • modifies implementation of prevention measures


Initial chd risk assessment l.jpg

Initial CHD Risk Assessment

  • Fasting lipoprotein profile

    • adults > 20 yrs old

    • every 5 years

    • TC, LDL-C, HDL-C, TG

  • Non-fasted blood sample

    • only TC and HDL-C usable

    • LDL-C = TC - HDL-C - (TG/5)


Atp iii classification of ldl cholesterol mg dl l.jpg

ATP III Classification of LDL- Cholesterol (mg/dl)

  • LDL Cholesterol

    • < 100 optimal

    • 100-129near/above optimal

    • 130-159borderline high

    • 160-189high

    • >190very high


Atp iii classification of total and hdl cholesterol mg dl l.jpg

ATP III Classification of Total and HDL Cholesterol (mg/dl)

  • Total Cholesterol

    • <200desirable

    • 200-239borderline high

    • >240high

  • HDL Cholesterol

    • <40low (bad)

    • >60high(good)


Slide10 l.jpg

Risk Category

LDL Goal(mg/dL)

LDL Level at Which to Initiate Therapeutic Lifestyle Changes (TLC) (mg/dL)

LDL Level at Which to ConsiderDrug Therapy (mg/dL)

CHD or CHD Risk Equivalents(10-year risk >20%)

<100

100

130 (100–129: drug optional)

2+ Risk Factors (10-year risk 20%)

<130

130

10-year risk 10–20%: 130

10-year risk <10%: 160

0–1 Risk Factor

<160

160

190 (160–189: LDL-lowering drug optional)

LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC)and Drug Therapy in Different Risk Categories


Chd risk equivalents l.jpg

CHD Risk Equivalents

  • Have risk of major coronary event equal to that of established CHD

  • Other forms of atherosclerotic disease

    • peripheral arterial disease

    • abdominal aortic aneurysm

    • symptomatic carotid artery disease

  • Diabetes

  • Multiple risk factors that confer a 10-year risk for CHD > 20%


Slide12 l.jpg

Risk Category

LDL Goal(mg/dL)

LDL Level at Which to Initiate Therapeutic Lifestyle Changes (TLC) (mg/dL)

LDL Level at Which to ConsiderDrug Therapy (mg/dL)

CHD or CHD Risk Equivalents(10-year risk >20%)

<100

100

130 (100–129: drug optional)

2+ Risk Factors (10-year risk 20%)

<130

130

10-year risk 10–20%: 130

10-year risk <10%: 160

0–1 Risk Factor

<160

160

190 (160–189: LDL-lowering drug optional)

LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC)and Drug Therapy in Different Risk Categories


Major risk factors that modify ldl goals l.jpg

Major Risk Factors that Modify LDL-Goals

  • Cigarette smoking

  • hypertension (BP>140/90 or on anti-hypertensive medication)

  • low HDL-C (<40mg/dl)

    • high HDL-C (>60mg/dl) “negative risk factor”

  • family history of premature CHD

    • 1o male relative < 55yrs

    • 1o female relative <65yrs

  • age

    • men > 45 yrs

    • women > 55 yrs


Estimating 10 year chd risk framingham risk score l.jpg

Estimating 10-Year CHD RiskFramingham Risk Score

  • Short Term Risk (10-yr) for myocardial infarction

    • Based on:

      • Age

      • Total Cholesterol

      • Smoking status

      • HDL

      • Systolic BP


Spreadsheet for determining framingham 10 yr risk l.jpg

Spreadsheet for determining Framingham 10-yr risk.

  • Downloadable at:

    • http://hin.nhlbi.nih.gov/atpiii/riskcalc.htm

  • Palm III Operating System download at:

    • http://hin.nhlbi.nih.gov/atpiii/atp3palm.htm

    • includes other information from ATP III


Categories of risk and ldl c goals l.jpg

Categories of Risk and LDL-C Goals


Slide17 l.jpg

Risk Category

LDL Goal(mg/dL)

LDL Level at Which to Initiate Therapeutic Lifestyle Changes (TLC) (mg/dL)

LDL Level at Which to ConsiderDrug Therapy (mg/dL)

CHD or CHD Risk Equivalents(10-year risk >20%)

<100

100

130 (100–129: drug optional)

2+ Risk Factors (10-year risk 20%)

<130

130

10-year risk 10–20%: 130

10-year risk <10%: 160

0–1 Risk Factor

<160

160

190 (160–189: LDL-lowering drug optional)

LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC)and Drug Therapy in Different Risk Categories


Therapeutic lifestyle changes in ldl lowering therapy l.jpg

Therapeutic Lifestyle Changes in LDL-lowering Therapy

  • TLC Diet

  • Therapeutic options to lower LDL-C

    • plant stanols/sterols (2g/d)

    • viscous soluble fiber (10-25 g/d)

  • Weight reduction

  • Increase physical activity


Tlc diet l.jpg

TLC diet

  • SFA: < 7% of Calories

  • PUFA: up to 10% of Calories

  • MUFA: up to 20% of Calories

  • Total Fat: 25-35% of Calories

  • CHO: 50-60% of Calories

  • fiber: 20-30g/d

  • Cholesterol: < 200mg/d


A model of steps in therapeutic lifestyle changes tlc l.jpg

Visit 3

Visit 2

Evaluate LDLresponse

If LDL goal notachieved, consideradding drug Tx

Evaluate LDLresponse

If LDL goal notachieved, intensifyLDL-Lowering Tx

Visit I

Begin LifestyleTherapies

A Model of Steps in Therapeutic Lifestyle Changes (TLC)

Visit N

6 wks

6 wks

Q 4-6 mo

MonitorAdherenceto TLC

  • Emphasizereduction insaturated fat &cholesterol

  • Encouragemoderate physicalactivity

  • Consider referral toa dietitian

  • Reinforce reductionin saturated fat andcholesterol

  • Consider addingplant stanols/sterols

  • Increase fiber intake

  • Consider referral toa dietitian

  • Initiate Tx forMetabolicSyndrome

  • Intensify weightmanagement &physical activity

  • Consider referral to a dietitian


Beyond ldl lowering metabolic syndrome as a secondary target of therapy l.jpg

Beyond LDL Lowering:Metabolic Syndrome as a Secondary Target of Therapy

  • Cluster of risk factors

  • Associated with insulin resistance

  • Enhance risk of CHD at any LDL-C level


Diagnosis of metabolic syndrome l.jpg

Diagnosis of Metabolic Syndrome

  • Three or more of the following:

  • Abdominal Obesity

    • men > 40” waist circumference

    • women > 35” waist circumference

  • Hypertriglyceridemia (>150 mg/dl)

  • Low HDL

    • men < 40 mg/dl

    • women < 50 mg/dl

  • Hypertension (>130/>85 mmHg)

  • Hyperglycemia (> 110 mg/dl)


Prevalence of the metabolic syndrome among us adults jama 287 356 359 2002 l.jpg

Prevalence of the Metabolic Syndrome Among US AdultsJAMA 287:356-359 (2002)

  • NHANES III (8814 adults)

  • Prevalence

    • 23.7% of adult population

      • 47 million Americans

    • increases with age

      • 6.7% of 20-29 yr olds

      • 43.5% of 60-69 yr olds

    • overall, prevalence similar in men and women

      • African-American women 57% higher

      • Mexican-American women 26% higher


Management of metabolic syndrome l.jpg

Management of Metabolic Syndrome

  • Control LDL-cholesterol

  • Weight Control

    • enhances LDL-C lowering

    • reduces all risk factors of metabolic syndrome

  • Physical Activity

    • reduces VLDL-TG

    • increases HDL-C

    • lowers LDL-C

    • lowers BP

    • reduces insulin resistance


Atp iii guidelines application l.jpg

ATP III Guidelines - Application

  • Step 1

    • Determine lipoprotein levels from fasted blood sample

  • LDL-cholesterol

    • primary target of therapy

    • Total cholesterol

    • HDL-cholesterol


Atp iii guidelines application26 l.jpg

ATP III Guidelines - Application

  • Step 2

    • Identify presence of clinical atherosclerotic disease that confer high risk

    • Clinical CHD

    • CHD risk equivalents


Atp iii guidelines application27 l.jpg

ATP III Guidelines - Application

  • Step 3

    • Determine presence of major risk factors (other than LDL)

  • cigarette smoking

  • hypertension or anti HPT meds

  • low HDL

  • family history

  • age


Atp iii guidelines application28 l.jpg

ATP III Guidelines - Application

  • Step 4

    • If 2+ risk factors (other than LDL) without CHD or CHD equivalent, assess 10-year CHD risk

    • Framingham tables

  • > 20% = CHD risk equivalent


Atp iii guidelines application29 l.jpg

ATP III Guidelines - Application

  • Step 5

    • Determine risk category

      • CHD or CHD Risk Equivalent

      • 2+ Risk Factors

      • 1-1 Risk Factors

  • Establish LDL goal

  • Determine need for TLC based on LDL

  • Determine level for drug consideration


Atp iii guidelines application30 l.jpg

ATP III Guidelines - Application

  • Step 6

    • Initiate TLC if LDL is above goal

  • TLC diet

  • Weight management

  • Increase physical activity


Atp iii guidelines application31 l.jpg

ATP III Guidelines - Application

  • Step 7

    • consider adding drug therapy if LDL exceeds recommended levels

  • Drugs + TLC simultaneously if CHD or CHD equivalent

  • Add drugs to TLC after 3 months for other risk categories


Atp iii guidelines application32 l.jpg

ATP III Guidelines - Application

  • Step 8

    • Identify metabolic syndrome and treat, if present after 3 months of TLC

  • Clinical identification

    • abdominal obesity

    • hypertriglyceridemia

    • low HDL

    • hypertension

    • hyperglycemia


Atp iii guidelines application33 l.jpg

ATP III Guidelines - Application

  • Step 8 (cont.)

  • Treat underlying causes

    • weight management

    • physical activity

  • Treat risk factors if they persist despite TLC

    • treat hypertension

    • use asprin

    • treat hypertriglyceridemia, low HDL


Atp iii guidelines application34 l.jpg

ATP III Guidelines - Application

  • Step 9

    • Treat elevated triglycerides

  • primary aim is to reach LDL goals

  • intensify weight management

  • increase physical activity

  • consider TG lowering drugs

  • if TG > 500mg/dl, 1st lower TG to prevent pancreatitis (VLFD)


Atp iii guidelines application35 l.jpg

ATP III Guidelines - Application

  • Step 9 (cont.)

    • Treatment of low HDL

  • first reach LDL goal

  • intensify weight management and increase physical activity

  • consider drug treatment if TG normal


Thanks the end l.jpg

Thanks!The End!


Estimate of 10 year risk for women framingham point scores l.jpg

Estimate of 10-Year Risk for Women (Framingham Point Scores)


Estimate of 10 year risk for women framingham point scores38 l.jpg

Estimate of 10-Year Risk for Women (Framingham Point Scores)


Estimate of 10 year risk for women framingham point scores39 l.jpg

Estimate of 10-Year Risk for Women (Framingham Point Scores)


Estimate of 10 year risk for women framingham point scores40 l.jpg

Estimate of 10-Year Risk for Women (Framingham Point Scores)


Estimate of 10 year risk for women framingham point scores41 l.jpg

Estimate of 10-Year Risk for Women (Framingham Point Scores)


Estimate of 10 year risk for women framingham point scores42 l.jpg

Estimate of 10-Year Risk for Women (Framingham Point Scores)


Estimate of 10 year risk for women framingham point scores43 l.jpg

Estimate of 10-Year Risk for Women (Framingham Point Scores)


Who me worry l.jpg

Who, me worry ???


  • Login